Frontiers in Immunology · Oct 31, 2026
Creatine, whey protein, and multimodal exercise for muscle preservation in cancer: a narrative review of the clinical evidence and a hypothesis-generating perspective on the muscle–tumor–immune axis
By Xin Wu
Cancer progression and anticancer therapy may disturb the bidirectional communication among skeletal muscle, tumor cells, and the immune system, thereby promoting systemic inflammation, metabolic impairment, muscle wasting, and reduced physical capacity. Accumulating evidence suggests that this muscle–tumor–immune interface is not simply a downstream result of cancer-associated catabolism, but could instead reflect a biologically linked network characterized by altered substrate use, inflammatory signaling, myokine-driven communication, immune-cell metabolism, and the tumor microenvironment (TME). Within this model, exercise and nutritional approaches might affect multiple elements of the network, although the size of these effects and their clinical importance likely depend on the specific context. This narrative review, reported according to the Scale for the Assessment of Narrative Review Articles (SANRA), primarily analyzes the clinical evidence on whether creatine, whey protein, and multimodal exercise preserve skeletal muscle in patients with cancer, and then considers, in a clearly labelled hypothesis-generating section, how these interventions could interact with immunometabolic and inflammatory processes, including T-cell exhaustion and the TME. It was considered how sarcopenia, anabolic resistance, and cancer-related metabolic alterations may shape these responses and potentially affect the biological setting in which anticancer therapies are administered. Human clinical evidence is distinguished from animal and in vitro studies to determine the translational strength of the proposed mechanisms. strength, and physical function, whereas creatine or whey protein added no consistent benefit beyond exercise. Direct evidence that these interventions modify T-cell exhaustion or the TME in patients is lacking, and preclinical studies report both antitumor effects of creatine on CD8+ T cells and pro-metastatic effects of creatine in some tumor models. Rather than presuming uniformly beneficial effects, we examine how intervention modality, exercise dose, nutritional status, tumor type, treatment context, and baseline muscle and metabolic phenotypes may explain heterogeneous findings. This integrative framework casts muscle as a dynamic element of the cancer–immune ecosystem and highlights testable links between exercise and nutritional interventions, immunometabolism, inflammation, T-cell exhaustion, and the preservation of skeletal muscle during cancer.